India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Natco Pharma (NTCPH IN): Getting Ready for the Next Moonshot

Event Driven: Natco Pharma’s Strategic Acquisition of Adcock Ingram

Cipla-Eli Lilly Deal: Strategic Masterstroke or Margin Mirage?

The Beat Ideas: Natco Pharma, The Cheapest Pharma Stock

The Beat Ideas: Welspun Living- Home Textile Giant Weaving Growth

Natco Pharma Q3 FY25 Earnings Analysis: 20% Lower Circuit Post Result

The Beat Ideas: KDDL- Precision Engineering with Luxury Retail

The Beat Ideas: CARE Ratings- India’s Only Homegrown CRA Reclaims Its Edge

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/natco-pharma-ltd" target="_blank" data-smartkarma-citation="entities:13634:1" rel="noopener">Natco Pharma (NTCPH IN)</a> achieved record consolidated revenue and profits in FY25 and holds a strong cash position over INR 3,500 crore.</li>
<li>However, the company estimates a significant potential dip in revenue (20%) and profits (30%) for FY26 due to US market pressures and high R&amp;D spend.</li>
<li>This signals near-term headwinds, while long-term growth remains tied to pipeline progress, particularly Semaglutide and Resplan launches in India, and strategic acquisitions.</li>
</ul>



Natco Pharma (NTCPH IN) achieved record consolidated revenue and profits in FY25 and holds a strong cash position over INR 3,500 crore.
However, the company estimates a significant potential dip in revenue (20%) and profits (30%) for FY26 due to US market pressures and high R&amp;D spend.
This signals near-term headwinds, while long-term growth remains tied to pipeline progress, particularly Semaglutide and Resplan launches in India, and strategic acquisitions.


NATCO Pharma Limited: Record Year Performance Overshadowed by Cautious FY26 Outlook